Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
MELBOURNE, Australia, Feb. 18, 2020 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel biologic therapies to treat eye diseases, today...
-
MELBOURNE, Australia, Jan. 07, 2020 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel biologic therapies to treat eye diseases, has completed...
-
MELBOURNE, Australia, Oct. 14, 2019 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical-stage biopharmaceutical company developing novel biologic therapies to treat back-of-the-eye diseases,...
-
MELBOURNE, Australia, Oct. 03, 2019 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical-stage biopharmaceutical company developing novel biologic therapies to treat back-of-the-eye diseases,...
-
MELBOURNE, Australia, Sept. 06, 2019 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical biopharmaceutical company developing novel biologic therapies for eye diseases, announced today that new...
-
MELBOURNE, Australia, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical biopharmaceutical company developing novel biologic therapies for eye diseases, announced today that...
-
OPT-302 Combination Therapy Demonstrated Superiority in Visual Acuity over Lucentis® Company to Host Conference Call Today at 9:00 AM AEST7:00PM EDT (Tuesday, August 6th U.S)-Dial-in details posted at...
-
MELBOURNE, Australia, Aug. 05, 2019 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT) will host a conference call to discuss the results of the Company’s Phase 2b clinical trial of OPT-302 in combination...
-
MELBOURNE, Australia, July 30, 2019 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT) is pleased to announce that the European Patent Office (EPO) has issued a “Notice of Intention to Grant” in relation...
-
MELBOURNE, Australia, May 15, 2019 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel biologic therapies to treat eye diseases, announced today...